Table 2.
Incidence of interstitial lung disease in clinical studies of trastuzumab deruxtecan
| Trial name | T-DXd (mg/kg) | No. of patients | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Total | ClinicalTrials.gov Identifier | References |
|---|---|---|---|---|---|---|---|---|---|---|
| DESTINY–Gastric01 | 6.4 | 125 | 3 (2.4) | 6 (4.8) | 2 (1.6) | 1 (0.8) | 0 | 12 (9.6) | NCT03329690 | [25] |
| DESTINY–Breast 01 | 5.4 | 184 | 20 (10.9)a | 1 (0.5) | 0 | 4 (2.2) | 25 (13.6) | NCT03248492 | [40] | |
| DESTINY–Lung 01 | 6.4 | 42 | 0b | 5 (11.9) | 0 | 0 | 0 | 5 (11.9) | NCT03505710 | [41] |
| DESTINY–CRC01 | 6.4 | 78 | 0 | 2 (2.6) | 1 (1.3) | 0 | 2 (2.6) | 5 (6.4) | NCT03384940 | [42] |
aGrade 1 and 2 combined
bOne case of potential grade 1 interstitial lung disease was pending adjudication at the time these data were collected